Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Hexadecasaccharide (SR123781A)
Hexadecasaccharide · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Hexadecasaccharide (SR123781A) | DRUG | - |
Inclusion Criteria: * A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours. * A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent Exclusion Criteria: * A person with known allergy or any...
Hexadecasaccharide is an investigational small molecule developed by Sanofi for cardiovascular conditions. It has been studied in patients with unstable angina or non-ST-segment elevation myocardial infarction, both of which fall under coronary atherosclerosis. It is a synthetic compound and remains in clinical development rather than being an approved therapy.
Hexadecasaccharide was studied for use in patients with unstable angina or non-ST-segment elevation myocardial infarction, conditions grouped under coronary atherosclerosis. The Phase 2 trial enrolled 1,257 patients aged 21 and older across multiple countries. It is investigational and has not been established as a treatment option for these patients.
Sanofi, which trades under the ticker SNY, is the developer of Hexadecasaccharide. The company sponsored the clinical program evaluating the compound in cardiovascular patients. Sanofi is listed on major exchanges including Nasdaq and Euronext Paris.
Hexadecasaccharide is in Phase 2 development. Its single registered trial, NCT00123565, has been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA or any other regulatory agency for marketing.
Hexadecasaccharide has been evaluated in one clinical trial, NCT00123565, titled Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction. The Phase 2 study was randomized, double blind, and enrolled 1,257 patients across the United States, Europe, Latin America, Asia, and Australia. It is now completed.
Yes, Hexadecasaccharide is also known as SR123781A. The two names refer to the same Sanofi compound, and the clinical trial registered as NCT00123565 lists it as Hexadecasaccharide (SR123781A). Readers searching for either name will find the same Phase 2 cardiovascular program.